The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemic.
The New Zealand Meningococcal Vaccine Strategy aims to end the devastating 14-year epidemic of B:4:P1.7b,4 group B meningococcal disease in New Zealand through a mass immunisation programme to all under 20 year olds using a tailor-made vaccine (MeNZB). This paper describes the scientific rationale, development, and key components of the New Zealand Meningococcal Vaccine Strategy. A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy.
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand.
Kerry
K
Sexton
Diana
D
Lennon
Philipp
P
Oster
Sue
S
Crengle
Diana
D
Martin
Kim
K
Mulholland
Teuila
T
Percival
Stewart
S
Reid
Joanna
J
Stewart
Jane
J
O'Hallahan
D004196:Disease Outbreaks / Q000517:prevention & control*; D006801:Humans; D017589:Immunization Programs; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000009:adverse effects; D038541:Neisseria meningitidis, Serogroup B / Q000276:immunology / Q000302:isolation & purification; D009520:New Zealand / Q000453:epidemiology; D011159:Population Surveillance; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors
D022401:Meningococcal Vaccines